ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "ff489893-f649-4b81-bf6a-787d98685e8a"}, "_deposit": {"id": "28453", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "28453"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00028453", "sets": ["2431"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "373", "bibliographicPageStart": "359", "bibliographicVolumeNumber": "81", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Cilostazol is a phosphodiesterase III-inhibiting antiplatelet agent that is often used to prevent stroke and peripheral artery disease, and its administration has shown significant improvements for cognitive impairment. We investigate the potential of cilostazol for reducing or restoring cognitive decline during con-valescent rehabilitation in patients with non-cardioembolic ischemic stroke. The study sample included 371 consecutive patients with lacunar (n = 44) and atherothrombosis (n = 327) subtypes of non-cardioembolic ischemic stroke (224 men and 147 women; mean age, 72.9 ± 8.1 years) who were required for inpatient convalescent rehabilitation. Their medical records were retrospectively surveyed to identify those who had received cilostazol (n = 101). Patients were grouped based on cilostazol condition, and Functional Independence Measure (FIM) scores (total and motor or cognitive subtest scores) were assessed both at admission and discharge. The gain and efficiency in FIM cognitive scores from admission to discharge were significantly higher in patients who received cilostazol than those who did not (p = 0.047 and p = 0.035, respectively); we found no significant differences in other clinical factors or scores. Multiple linear regression analysis confirmed that cilostazol was a significant factor in FIM cognitive scores at discharge (β = 0.041, B = 0.682, p = 0.045); the two tested dosages were not significantly different (100 mg/day, n = 43; 200 mg/day, n = 58). Cilostazol can potentially improve cognitive function during convalescent rehabilitation of patients with non-cardioembolic ischemic stroke, although another research must be needed to confirm this potential.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.81.3.359", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/813.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Senda, Joe"}], "nameIdentifiers": [{"nameIdentifier": "93107", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ito, Keiichi"}], "nameIdentifiers": [{"nameIdentifier": "93108", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kotake, Tomomitsu"}], "nameIdentifiers": [{"nameIdentifier": "93109", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanamori, Masahiko"}], "nameIdentifiers": [{"nameIdentifier": "93110", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kishimoto, Hideo"}], "nameIdentifiers": [{"nameIdentifier": "93111", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kadono, Izumi"}], "nameIdentifiers": [{"nameIdentifier": "93112", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakagawa-Senda, Hiroko"}], "nameIdentifiers": [{"nameIdentifier": "93113", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Wakai, Kenji"}], "nameIdentifiers": [{"nameIdentifier": "93114", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Katsuno, Masahisa"}], "nameIdentifiers": [{"nameIdentifier": "93115", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nishida, Yoshihiro"}], "nameIdentifiers": [{"nameIdentifier": "93116", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ishiguro, Naoki"}], "nameIdentifiers": [{"nameIdentifier": "93117", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2019-09-04"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "03_Senda.pdf", "filesize": [{"value": "3.0 MB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 3000000.0, "url": {"label": "03_Senda.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/28453/files/03_Senda.pdf"}, "version_id": "ad86827e-7c36-484b-af4a-ff02bb035d28"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Cilostazol", "subitem_subject_scheme": "Other"}, {"subitem_subject": "ischemic stroke", "subitem_subject_scheme": "Other"}, {"subitem_subject": "FIM cognitive", "subitem_subject_scheme": "Other"}, {"subitem_subject": "convalescent rehabilitation", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study"}]}, "item_type_id": "9", "owner": "1", "path": ["2431"], "permalink_uri": "https://doi.org/10.18999/nagjms.81.3.359", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-09-04"}, "publish_date": "2019-09-04", "publish_status": "0", "recid": "28453", "relation": {}, "relation_version_is_last": true, "title": ["Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study"], "weko_shared_id": 3}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 81(3)

Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study

https://doi.org/10.18999/nagjms.81.3.359
https://doi.org/10.18999/nagjms.81.3.359
ce721127-073d-4c6d-af2a-166ab0563277
名前 / ファイル ライセンス アクション
03_Senda.pdf 03_Senda.pdf (3.0 MB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2019-09-04
タイトル
タイトル Cilostazol use is associated with FIM cognitive improvement during convalescent rehabilitation in patients with ischemic stroke: a retrospective study
著者 Senda, Joe

× Senda, Joe

WEKO 93107

Senda, Joe

Search repository
Ito, Keiichi

× Ito, Keiichi

WEKO 93108

Ito, Keiichi

Search repository
Kotake, Tomomitsu

× Kotake, Tomomitsu

WEKO 93109

Kotake, Tomomitsu

Search repository
Kanamori, Masahiko

× Kanamori, Masahiko

WEKO 93110

Kanamori, Masahiko

Search repository
Kishimoto, Hideo

× Kishimoto, Hideo

WEKO 93111

Kishimoto, Hideo

Search repository
Kadono, Izumi

× Kadono, Izumi

WEKO 93112

Kadono, Izumi

Search repository
Nakagawa-Senda, Hiroko

× Nakagawa-Senda, Hiroko

WEKO 93113

Nakagawa-Senda, Hiroko

Search repository
Wakai, Kenji

× Wakai, Kenji

WEKO 93114

Wakai, Kenji

Search repository
Katsuno, Masahisa

× Katsuno, Masahisa

WEKO 93115

Katsuno, Masahisa

Search repository
Nishida, Yoshihiro

× Nishida, Yoshihiro

WEKO 93116

Nishida, Yoshihiro

Search repository
Ishiguro, Naoki

× Ishiguro, Naoki

WEKO 93117

Ishiguro, Naoki

Search repository
キーワード
主題Scheme Other
主題 Cilostazol
キーワード
主題Scheme Other
主題 ischemic stroke
キーワード
主題Scheme Other
主題 FIM cognitive
キーワード
主題Scheme Other
主題 convalescent rehabilitation
抄録
内容記述 Cilostazol is a phosphodiesterase III-inhibiting antiplatelet agent that is often used to prevent stroke and peripheral artery disease, and its administration has shown significant improvements for cognitive impairment. We investigate the potential of cilostazol for reducing or restoring cognitive decline during con-valescent rehabilitation in patients with non-cardioembolic ischemic stroke. The study sample included 371 consecutive patients with lacunar (n = 44) and atherothrombosis (n = 327) subtypes of non-cardioembolic ischemic stroke (224 men and 147 women; mean age, 72.9 ± 8.1 years) who were required for inpatient convalescent rehabilitation. Their medical records were retrospectively surveyed to identify those who had received cilostazol (n = 101). Patients were grouped based on cilostazol condition, and Functional Independence Measure (FIM) scores (total and motor or cognitive subtest scores) were assessed both at admission and discharge. The gain and efficiency in FIM cognitive scores from admission to discharge were significantly higher in patients who received cilostazol than those who did not (p = 0.047 and p = 0.035, respectively); we found no significant differences in other clinical factors or scores. Multiple linear regression analysis confirmed that cilostazol was a significant factor in FIM cognitive scores at discharge (β = 0.041, B = 0.682, p = 0.045); the two tested dosages were not significantly different (100 mg/day, n = 43; 200 mg/day, n = 58). Cilostazol can potentially improve cognitive function during convalescent rehabilitation of patients with non-cardioembolic ischemic stroke, although another research must be needed to confirm this potential.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.81.3.359
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/813.html
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
ISSN(Online)
収録物識別子タイプ ISSN
収録物識別子 2186-3326
書誌情報 Nagoya Journal of Medical Science

巻 81, 号 3, p. 359-373, 発行日 2019-08
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 10:02:23.805431
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3